Does aging reduce kidney and liver clearance capacity for some xenobiotics?

At age 83, age-associated changes make reduced clearance of selected drugs and other xenobiotics more plausible, but chronological age cannot determine clearance capacity for this individual.

Clinical evidence

• Renal function commonly declines with age. In healthy-adult longitudinal studies, measured GFR declined by approximately 0.37–1.07 mL/min/1.73 m²/year; mean inulin-measured GFR fell from 122.8 mL/min/1.73 m² at age 20 to 65.3 mL/min/1.73 m² at age 90. Reduced GFR and tubular function directly reduce elimination and promote accumulation of renally cleared compounds.
• Hepatic functional reserve also tends to decline: liver mass and hepatic blood flow decrease by approximately 17–46%, while in-vivo Phase I metabolism declines roughly 30–50%. These changes can reduce first-pass metabolism and clearance, particularly for high-extraction compounds.

Mechanisms and xenobiotic specificity

• Renal elimination depends on filtration, renal perfusion, and tubular secretion/reabsorption. Thus, impaired measured kidney function has direct relevance to exposure from renally eliminated medications.
• Lower liver volume/perfusion and Phase I activity particularly affect flow-dependent, high-extraction drugs. Effects are not universal: Phase II pathways may be relatively preserved, and capacity-limited clearance depends on intrinsic metabolism and protein binding.
• Aging-related lower total body water and lean mass, with greater body fat, can further alter distribution, unbound concentrations, and duration of effect for certain agents.

Individual assessment

• Age alone does not establish impaired clearance. Comorbidity, frailty, sarcopenia, nutrition, inflammation, pharmacogenetics, protein binding, and interacting drugs substantially modify risk.
• For renal dosing, use serum creatinine within a validated eGFR approach and consider absolute mL/min; in sarcopenia, creatinine may appear falsely reassuring, making cystatin C–based combined estimates or measured GFR useful when decisions are high stakes.

Bottom line

• Aging commonly reduces renal function and selected hepatic clearance pathways, but at 83 years individualized renal measurement, drug-specific hepatic assessment, and clinical monitoring—not age-based assumptions—should guide xenobiotic dosing and safety.